Loading clinical trials...
Loading clinical trials...
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP)...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Shirley Ryan AbilityLab
NCT07511244 · Bladder and Bowel Dysfunction, SCI - Spinal Cord Injury
NCT05630235 · SCI - Spinal Cord Injury, Neuropathic Pain
NCT03698149 · ALS, SCI - Spinal Cord Injury, and more
NCT06643312 · SCI - Spinal Cord Injury
NCT06596174 · SCI - Spinal Cord Injury
Shirley Ryan Abilitylab
Chicago, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions